Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial (Theratechnologies Inc)

Edit Public Technologies 28 Apr 2016
(Source. Theratechnologies Inc) 151416db-d07a-46b5-95ab-1c613dd198ae.pdf. Theratechnologies Announces Completion of Enrollment for Phase III. Ibalizumab Trial Montreal, Canada - April 27, 2016 - Theratechnologies Inc. (Theratechnologies) (TSX ... The last patient enrolled in the study has entered the initial 7-day control period ... The antibody is a novel CD4-directed HIV entry-inhibitor currently in a late stage Phase III clinical trial ... 2....

Biomarker discovery offers hope for new TB vaccine (London School of Hygiene & Tropical Medicine)

Edit Public Technologies 28 Apr 2016
(Source. London School of Hygiene & Tropical Medicine). Thursday, 14 April 2016. Researchers have discovered new biomarkers for TB which could improve the chances of developing an effective TB vaccine, suggests new research published in the journal Nature Communications ... It is currently very difficult to determine whether it will work or not ... One - levels of activated HLA-DR+CD4+ T-cells - was linked to higher TB disease risk ... Image....

Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial

Edit Stockhouse 28 Apr 2016
MONTREAL, QUEBEC--(Marketwired - April 27, 2016) - Theratechnologies Inc ... This open label, single arm Phase III study is the last clinical trial required by the FDA to complete the BLA submission ... About Ibalizumab. Ibalizumab is a humanized monoclonal antibody for the treatment of HIV-1 infection. The antibody is a novel CD4-directed HIV entry-inhibitor currently in a late stage Phase III clinical trial. About Theratechnologies ... ....

Remarkably low affinity of CD4 for pMHC II [Immunology and Inflammation]>

Edit PNAS 26 Apr 2016
The αβ T-cell coreceptor CD4 enhances immune responses more than 1 million-fold in some assays, and yet the affinity of CD4 for its ligand, peptide-major histocompatibility class II (pMHC II) on antigen-presenting cells, is so weak that it was previously unquantifiable. Here, we report that a soluble form of CD4... ....

Role of Global Fund on TB, HIV and Malaria Control Programme (Ministry of Health and Family Welfare of the Republic of India)

Edit Public Technologies 26 Apr 2016
(Source. Ministry of Health and Family Welfare of the Republic of India) ... At present through the New Funding Model grant Global Fund supports implementation of ART Centres by providing cost of ARV drugs, purchasing of CD4 Machines, scale up of viral load testing, Airborne Infection Control activities, Development of IT based monitoring and evaluation system, approved operational researches, and a part of human resource costs ... Year ... %....

Johns Hopkins Physicians Elected to And Honored by American Association of Physicians and American Society for Clinical Investigation (Johns Hopkins Health System)

Edit Public Technologies 26 Apr 2016
(Source. Johns Hopkins Health System). Eight Johns Hopkins physicians have been elected to the Association of American Physicians (AAP) and two have been elected to the American Society for Clinical Investigation (ASCI) ... Agre's Kober Medal was presented to him by Paul B ... --William R ... --Peter J ... In 1995, his laboratory provided the first demonstration that latently infected memory CD4+ T cells were present in patients with HIV-1 infection....

Cancer immunotherapy finds success in study of leukemia patients

Edit The Oklahoman 25 Apr 2016
It’s the latest advance in what’s widely regarded as a potential new pillar of cancer care ... 19, 2014 ... “All of these treatments have worked to date ... This study was the first to show that instead of using all of the T-cells collected from patients, researchers could use two subtypes, called CD4 cells and CD8 cells, to create a stronger, longer-lasting remission. The CD4 cells are known as “helper cells,” which boost the immune response....

J’Den Cox Strikes Gold At Olympic Qualifying Tournament To Earn Trip To First Olympics (United States Olympic Committee)

Edit Public Technologies 24 Apr 2016
(Source. United States Olympic Committee). Print. By Craig Bohnert . April 24, 2016, 8.10 a.m. (ET). Prior to this weekend, J'Den Cox had traveled no further from his hometown of Columbia, Missouri, than to Reno, Nevada ... weight class to do just that ... In fact, when he won the U.S ... Olympic Team ... Original Document. https.//cd4.teamusa.org/News/2016/April/24/JDen-Cox-Strikes-Gold-At-Olympic-Qualifying-Tournament-To-Earn-Trip-To-First-Olympics....

Western Cape Health on influenza season (South Africa Government)

Edit Public Technologies 22 Apr 2016
Chronic pulmonary disease (including asthma) Cardiovascular disease (except hypertension) Renal, hepatic, neurological and haematological disorders Metabolic disorders (including diabetes mellitus) Morbid obesity (BMI≥40) Immunosuppression (including HIV-infected persons with CD4 counts over 100/mm3 Pregnant Women (all stages of pregnancy) Children ......

Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at American Association for Cancer Research (AACR) Annual Meeting 2016 (Provectus Pharmaceuticals Inc)

Edit Public Technologies 22 Apr 2016
... in the M05 tumor model.' They also conclude that 'the effect of combination therapy with IL PV-10 and PD-1 blockade is mediated by CD8+ T cells, and depletion of either CD4+ T cells or CD25+ Tregs enhances anti-tumor immunity in the M05 melanoma model.' The abstract of the poster (number 4978) may be viewed at http.//www.abstractsonline.com/4978....

Daily iNAV and Portfolio Disclosure (ISE - The Irish Stock Exchange plc)

Edit Public Technologies 22 Apr 2016
(Source. ISE - The Irish Stock Exchange plc). STOCK EXCHANGE ANNOUNCEMENT - FOR IMMEDIATE RELEASE. PIMCO Fixed Income Source ETFs Plc (the 'Fund'). PIMCO US Dollar Short Maturity Source UCITS ETF. (the 'Sub-Fund'). Re. Daily iNAV and portfolio disclosure. 22 April 2016. ______________________________________________. iNAV per share. 100.780168 as of 16.30 GMT on 21 April. Number of outstanding shares. 14,240,004 ... CD 2007-CD4 A1A WM16 WC5.720700....

Omega Diagnostics insists prognosis looks ‘bright’

Edit Scotsman 21 Apr 2016
The company has suffered setbacks with its testing kit that checks the immune systems of HIV patients, and last year moved the manufacturing of its Visitect CD4 device in-house after field trials in Kenya revealed “just below optimal performance” ... with respect to CD4, much progress has been made.”....

Trading Update and Notice of Results (Omega Diagnostics Group plc)

Edit Public Technologies 21 Apr 2016
(Source. Omega Diagnostics Group plc) Change of adviser. 21 April 2016 ... Omega (AIM ... + 19% ... CD4 update ... We have continued to move forward with our Visitect® CD4 development programme ... While there are still challenges ahead, we remain confident that we will continue to see positive progress with the Visitect® CD4 test development and together with the growth strategy as outlined we remain optimistic for a bright future for the Company."....
×